Published Technical Disclosure Archive

AI-Enhanced Ex-Vivo Lung Perfusion System Innovation

Publication ID: 24-11856944_0005_PTD
Published: October 26, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “AI-Enhanced Ex-Vivo Lung Perfusion System Innovation,” Published Technical Disclosure No. 24-11856944_0005_PTD, Published October 26, 2025, available at https://archive.pr1or.art/24-11856944_0005_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,856,944.

Background and Problem Solved

Current organ preservation techniques, as described in the original patent, are limited by their reliance on hypothermic storage and chemical perfusion solutions. The present invention addresses these limitations by introducing a paradigm shift in ex-vivo lung perfusion, enabling real-time adaptation to changing lung conditions, predictive analytics, and decentralized data tracking.

Novelty and Inventive Step

The present invention's novelty lies in the integration of artificial intelligence, machine learning, and bio-inspired materials to create a real-time adaptive ex-vivo lung perfusion system. The inventive step is the use of these technologies to overcome the limitations of current organ preservation techniques, enabling a paradigm shift in the field.

Alternative Embodiments and Variations

Alternative embodiments of the invention may include the use of different machine learning algorithms, varying types of bio-inspired materials, or alternative decentralized data tracking platforms. Variations of the invention could also include the application of these technologies to other organs or tissues, expanding the scope of the invention beyond lung perfusion.

Potential Commercial Applications and Market

The intelligent ex-vivo lung perfusion system has significant commercial potential in the organ transplantation and regenerative medicine industries, with potential applications in hospitals, research institutions, and biotechnology companies. The market for this technology is expected to grow as the demand for organ transplantation increases, driven by the rising need for effective organ preservation solutions.

CPC Classifications

SectionClassGroup
A A01 A01N1/0226
A A01 A01N1/0247

Field of Art

Biomedical engineering, specifically organ preservation techniques, ex-vivo organ perfusion systems, and medical device technologies focused on lung transplantation and organ care

Person of Ordinary Skill (PHOSITA) Profile

A biomedical engineer or medical device researcher with expertise in organ preservation, advanced perfusion techniques, knowledge of physiological parameters, and familiarity with emerging medical technologies including AI and sensor-based systems

Obviousness Rationale

A PHOSITA would recognize that the PTD's proposed variations represent predictable extensions of existing organ perfusion technologies by integrating known computational and sensing approaches to enhance the source patent's fundamental lung preservation method. The proposed AI-driven and sensor-based adaptations directly address existing limitations in organ preservation by providing real-time monitoring and dynamic adjustment capabilities. These technological improvements would be considered obvious incremental innovations within the field of ex-vivo organ care.

Obvious Combinations & Variations

Source Patent Element
Perfusion liquid with specific nutrient and chemical composition for lung preservation
PTD Variation
Machine learning algorithms for dynamically adjusting perfusion solution parameters based on real-time sensor data
Obviousness Reasoning
A PHOSITA would find it obvious to apply computational optimization techniques to existing perfusion protocols, as machine learning represents a known method for refining complex biological systems with multiple variables
Source Patent Element
Ex-vivo lung preservation method involving chemical perfusion
PTD Variation
Micro-robotic systems for dynamically adjusting perfusion flow and pressure
Obviousness Reasoning
Integrating robotic control into medical perfusion systems is a predictable technological progression, representing a known technique for improving precision and adaptability of medical procedures
Source Patent Element
Static preservation solution for donor lungs
PTD Variation
Bio-inspired self-healing materials that adapt to changing lung morphology
Obviousness Reasoning
Developing responsive materials for medical applications is an obvious extension of existing materials science, representing a finite set of design solutions for improving organ preservation technologies
Source Patent Element
Method of organ perfusion with specific chemical composition
PTD Variation
Blockchain-based platform for tracking and validating perfusion data
Obviousness Reasoning
Applying distributed ledger technologies to medical data tracking represents a predictable technological improvement in medical record management and transparency
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11856944 and the disclosed technological variations, a person of ordinary skill in the art would find the proposed ex-vivo lung perfusion innovations obvious and non-patentable, as they represent predictable technological extensions utilizing known computational, sensing, and materials science techniques to address existing limitations in organ preservation methodologies.

Original Patent Information

Patent NumberUS 11,856,944
TitleOrgan care solution for ex-vivo machine perfusion of donor lungs
Assignee(s)TRANSMEDICS, INC.